Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
Authors
Keywords
Small cell lung cancer, Brain metastases, Tumor infiltrating lymphocytes, PD-L1 expression, Immune checkpoint inhibitor
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 130, Issue 1, Pages 19-29
Publisher
Springer Nature
Online
2016-07-19
DOI
10.1007/s11060-016-2216-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer
- (2015) Qiu-Xia Qu et al. TUMOR BIOLOGY
- Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer
- (2015) Reina Yajima et al. Breast Cancer
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
- (2015) Silvia Darb-Esfahani et al. Oncotarget
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
- (2015) K. M. Mahoney et al. Cancer Immunology Research
- Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment
- (2015) Kar Wai Tan et al. OncoImmunology
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
- (2015) Aitziber Buqué et al. OncoImmunology
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
- (2015) Anna S Berghoff et al. OncoImmunology
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
- (2014) Anna Sophie Berghoff et al. HISTOPATHOLOGY
- Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
- (2014) J S Ross et al. JOURNAL OF CLINICAL PATHOLOGY
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation
- (2014) Hui Zhu et al. Radiation Oncology
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) M. Fruh et al. ANNALS OF ONCOLOGY
- The first survival score for patients with brain metastases from small cell lung cancer (SCLC)
- (2013) Dirk Rades et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry
- (2013) Adelheid Woehrer CLINICAL NEUROPATHOLOGY
- PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
- (2013) Anna Sophie Berghoff et al. CLINICAL NEUROPATHOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma
- (2013) Anna S. Berghoff et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels
- (2012) S. Durand-Panteix et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma
- (2011) K Hotta et al. BRITISH JOURNAL OF CANCER
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
- (2011) Paul W. Sperduto et al. JOURNAL OF CLINICAL ONCOLOGY
- Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor
- (2011) Anna M Dahlin et al. MODERN PATHOLOGY
- Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer
- (2010) Nathan R. Foster et al. CANCER
- The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry
- (2009) Adelheid Wöhrer et al. JOURNAL OF NEURO-ONCOLOGY
- Immune-mediated dormancy: an equilibrium with cancer
- (2008) Michele W. L. Teng et al. JOURNAL OF LEUKOCYTE BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started